Search company, investor...

Active Pass Pharmaceuticals

About Active Pass Pharmaceuticals

Active Pass is a Canadian biotechnology company that is engaging in genomic-based drug discovery and is developing drugs that inhibit ABC transporters. ABC or (ATP binding cassette) is a term that describes the interconnected group of molecular engines or pumps that function as a transportation system which moves compounds across the biological membranes. These ABCs are very closely associated with human diseases like Alzheimer's disease, diabetes, asthma, and hypertension. The Active Pass management team is an accomplished group with experience in many aspects of drug discovery and development. Besides employing full time pharmaceutical development professionals, Active Pass has made wise use of a group of several key partnerships with different pharmaceutical groups. The company cultivates these partnerships in order to access new capabilities or expertise to advance the company's own technologies. More specifically, these partnerships include the Vaccines and Infectious Diseases Organization as well as the National Institute of Health). The company hopes to add new personnel to cover emerging areas of emphasis like clinical and regulatory affairs, business development and finance as they grow.

Headquarters Location

British Columbia,

Canada

Missing: Active Pass Pharmaceuticals's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Active Pass Pharmaceuticals's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Active Pass Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Active Pass Pharmaceuticals is included in 1 Expert Collection, including Diabetes.

D

Diabetes

1,903 items

Active Pass Pharmaceuticals Frequently Asked Questions (FAQ)

  • Who are Active Pass Pharmaceuticals's competitors?

    Competitors of Active Pass Pharmaceuticals include MicuRx Pharmaceuticals, Carmot Therapeutics, DiscoveryBioMed, InterveXion Therapeutics, Cognition Therapeutics, Sequoia Sciences, Knopp Biosciences, Visiopharm, Echelon Biosciences, Promentis Pharmaceuticals and 36 more.

Compare Active Pass Pharmaceuticals to Competitors

Echelon Biosciences Logo
Echelon Biosciences

Echelon Biosciences is a company that received a SBIR Phase I grant for a project entitled: Near Infrared Substrates for Imaging Autotaxin Activity In Vivo. Their project aims to synthesize ATXRed, an in vivo imaging agent that is specifically activated by the enzymatic activity of autotaxin. Autotaxin is an extracellular enzyme that generates the phospholipid growth factor lysophophatidic acid (LPA). LPA is involved in a variety of biological functions, such as angiogenesis, wound healing, brain development, immunological competence and the regulation of blood pressure. Both LPA and autotaxin have also been implicated in numerous diseases, especially metastatic cancer. Autotaxin was identified as one of the 40 most induced genes in aggressive breast cancer. The broader impacts of this research are the discovery and commercialization of tools that easily highlight specific biological pathways in living organisms. ATXRed will be welcomed by basic researchers in many fields associated with autotaxin and LPA. However, the utility extends beyond the basic research sphere. ATXRed smart probes could also aid pharmaceutical researchers searching for pharmacological inhibitors of autotaxin and LPA receptor agonists and antagonists. ATXRed would be a powerful tool in many rodent models of human cancer. In vivo autotaxin imaging probes could also aid in the clinic by helping to identify and monitor disease progression and treatment. Ultimately, ATXRed could help guide surgical resection of tumorstumors previously identified by the smart probe to have elevated autotaxin activity. In total, ATXRed probes have the potential to impact basic research, drug discovery and the clinic as a prime example of molecular medicine applied from bench to bedside.

W
Welichem Biotech

Welichem Biotech Inc. ("Welichem", TSX-V: WBI) is engaged in the discovery and development of small molecule therapeutics. Using its Symbiochem technology platform, the Company has developed a robust pipeline of patent-protected compounds that target autoimmune/inflammatory diseases and cancers. Welichem's lead drug candidate, WBI-1001, targets autoimmune/inflammatory skin disorders, such as psoriasis and eczema. A phase I clinical trial of WBI-1001, done in Montreal, in patients with psoriasis has shown a very good safety profile and promising efficacy. As well, the application of WBI-1001 cream against atopic dermatitis (a type of eczema) in a phase IIa clinical trial also has been completed in Canada, with the final report pending in the third quarter of 2008. Welichem plans to all the necessary Phase II Clinical Trials against psoriasis and eczema in the near future. In the company's pipeline, WBI-1001 related compounds are being evaluated also for their therapeutic potential against other autoimmune diseases such as, inflammatory bowel disease and rheumatoid arthritis. Welichem's other lead drug candidate, WBI-2100, selectively targets certain types of hard-to-treat cancerous tumours. This is achieved in part through inhibition of angiogenesis and metastasis. Animal tests have shown that WBI-2100 is effective as a monotherapy and also in increasing the effectiveness of several commonly used chemotherapeutic products. The uniqueness of this small molecule cancer chemotherapeutic is that in pre-clinical studies it increases the number of neutrophils in the peripheral blood. The boosting of neutrophils in animal studies in the presence of the cancer therapeutic, cyclophosphamide, supports its potential therapeutic application for chemotherapy induced neutropenia. With its proven Symbiochem; technology platform, Welichem will advance its pipeline of drug candidates at a rate and time commensurate with resources and target need, and is in a strong position to contribute effectively to productive drug discovery and development partnerships.

V
VivoPath

VivoPath is a preclinical screening company, offering the company's clients discovery and development services for in vivo testing. VivoPath aims to provide integrated in vivo studies led by established experts in drug development. Efficacy is established for animal models in the areas of metabolic disease, inflammation, neurodegenerative disease, and infectious diseases. Formulation screening is carried out to select the most appropriate delivery system for administration. Pharmacokinetic evaluation is carried out to assess exposure and bioavailability. Tolerability is assessed with evaluations of clinical signs, clinical chemistry and hematology. The resulting program aims to deliver the client an in vivo therapeutic index (TI) report on which to assess candidates for subsequent development. VivoPath can also help clients at any individual step in this preclinical screening process. VivoPath's commitment is to provide scientific expertise in in vivo drug discovery in order to increase productivity from research into drug development.

C
Carmot Therapeutics

Carmot Therapeutics is applying its technology, Chemotype Evolution, to address unmet chemical needs in drug discovery, focusing on high-profile targets for which drug leads have been difficult to identify. Carmot has built and optimized this platform to rapidly and efficiently unlock therapeutic target space not currently accessible to conventional small molecule technologies. Carmot is currently using Chemotype Evolution to discover novel drug candidates targeting validated pathways in metabolic disease, oncology, and inflammation. The company was founded in 2008 and is based in Berkeley, California.

Trana Discovery Logo
Trana Discovery

Trana Discovery, a drug discovery technology company, aims to help its partners find classes of drugs for the treatment of serious viral, fungal, and bacterial infectious diseases. The technology identifies compounds that work through a mechanism of action: inhibition of the target pathogen's ability to use transfer RNA (tRNA) essential for protein synthesis or replication. The use of Trana Discovery technology can unlock the value " scientific, human, and financial " hidden in drug compound libraries, expedite the discovery of drugs, and provide opportunities for exclusive rights to drug classes.

A
Alzeim

Alzheimer's Disease is a modern curse that negates the many benefits from modern medicine and improved standards of hygiene and living. As the human population life-span is increased, a larger percentage of people will succumb to debilitating and distressing memory loss. Alzeim is dedicated to making available a natural plant alkaloid " Galanthamine (also widely called Galantamine) - that is proven to be a drug in the alleviation of memory-loss symptoms.nIt has few adverse side-effects and is currently extremely expensive to produce either from wild plants or by synthesis. By the application of research adding to its existing framework of knowledge, the company is establishing a new agri-industry in an upland region of Wales. Once production is adequate, it will make Galanthamine more widely available and affordable. Daffodils grown in the Black Mountains - helping Alzheimer's patientsnnGalanthamine has been known for some time as one of the few effective treatments for patients at certain stages of Alzheimer's Disease, having been produced in its natural form from plants found in the wild " principally in the Balkan region. This natural alkaloid is currently in short supply and because of the large number of potential patients (c. 700,000 currently in UK) is a very expensive treatment in total for a health provider to assume. In Scotland all patients who can benefit from it, and from related drugs, have access on prescription, but in England and Wales, the National Institute for Clinical Excellence (NICE) has decided to withdraw all anti-cholinesterase treatments from the National Health Service as regards new patients, because of the high total cost of branded medicines still subject to restrictive product licence. That decision has caused an outcry from sufferers and their families, and is being disputed in the High Court. It may not be resolved until after the drugs are able to be produced and sold in generic form. Nevertheless, global demand for Galanthamine is expanding rapidly. Alzeim expects to be able to provide much-needed extra quantities of the drug at lower prices thereby enabling many more patients to benefit from this treatment. Field trials, plant species and variety screening and laboratory extraction, purification and analysis work undertaken initially in co-operation with the IGER institute of University of Wales, Aberystwyth, indicated that a feasible route existed to produce Galanthamine economically in special regimes in parts of Mid-Wales. Since then, using mechanization under agronomic conditions, Alzeim has developed new production regimes with its own cultivars.nAmong other academic collaborations Alzeim is working on aspects of Galanthamine extraction and purification with the University of Manchester.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.